Defining the Mechanistic Basis for Neurofibromatosis-1 Nervous System Disease Heterogeneity

定义神经纤维瘤病-1神经系统疾病异质性的机制基础

基本信息

  • 批准号:
    10534120
  • 负责人:
  • 金额:
    $ 76.25万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-12-01 至 2024-11-30
  • 项目状态:
    已结题

项目摘要

Project Summary As we enter into an era of personalized (precision) medicine, it becomes increasingly important to define the factors that confer disease risk and outcome. Since these determinants cannot be easily controlled in human epidemiological studies, genetically-engineered mouse (GEM) strains and human induced pluripotent stem cell (iPSC) lines provide mechanistically-tractable platforms to define the factors underlying disease heterogeneity and translate them to risk assessment tools and treatments. This challenge is nicely illustrated by Neurofibromatosis type 1 (NF1), a rare neurogenetic condition caused by a germline mutation in the NF1 gene. Individuals with NF1 are prone to the development of a wide variety of neurological problems, including cognitive and behavioral problems (60-70% of children) and low-grade brain tumors (~20% of children). While establishing the diagnosis of NF1 in an infant is straightforward, it is currently not possible to predict which child will develop future medical problems, determine whether there will be clinical progression requiring treatment, or institute effective therapies that specifically target the subtype of clinical manifestation in that individual. The pressing challenge for clinicians and researchers alike is to dissect the genetic, cellular, molecular, and systems-level etiologies for these common neurologic problems with the ultimate goal of developing prognostic and precision neurology approaches for children affected with NF1. In this proposal, we plan to leverage human NF1-patient iPSCs, mice engineered with patient germline NF1 gene mutations, bioinformatics and systems biology approaches, and novel modeling approaches to mechanistically define the factors that underlie the heterogeneity that characterizes NF1. The overall mission of this project is to establish the etiologic bases for NF1 clinical variability and to create a blueprint for future clinical application necessary to transform the care of individuals with NF1 from a reactive to a more proactive approach.
项目摘要 随着我们进入个性化(精确)医学时代,定义 决定疾病风险和结果的因素。由于这些决定因素在人类体内不容易控制 流行病学研究,基因工程小鼠(GEM)品系和人类诱导的多能干细胞 (IPSC)系列提供了机械上易于处理的平台,以定义疾病异质性的潜在因素 并将其转化为风险评估工具和治疗方法。这一挑战在以下方面得到了很好的说明 神经纤维瘤病1型(NF1),一种罕见的神经遗传学疾病,由NF1基因的胚系突变引起。 患有NF1的人容易出现各种各样的神经问题,包括 认知和行为问题(60%-70%的儿童)和低级别脑瘤(约20%的儿童)。而当 在婴儿中确定NF1的诊断很简单,目前还不可能预测哪种情况 孩子将来会出现医疗问题,决定是否会有临床进展需要 治疗,或制定专门针对临床表现亚型的有效疗法 个人的。临床医生和研究人员面临的紧迫挑战是剖析基因、细胞和 这些常见神经问题的分子和系统水平的病因最终目标是 为受NF1影响的儿童开发预后和精确的神经学方法。在这 提案中,我们计划利用人类NF1患者iPSCs,即用患者生殖系NF1基因改造的小鼠 突变、生物信息学和系统生物学方法,以及新的机械建模方法 定义构成NF1异质性特征的因素。该项目的总体任务是 建立NF1临床变异的病因学基础,勾画未来临床应用蓝图 有必要将对NF1患者的护理从被动方式转变为更主动的方式。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David H Gutmann其他文献

Pediatric low-grade glioma: State-of-the-art and ongoing challenges.
儿科低级别胶质瘤:最先进的技术和持续的挑战。
  • DOI:
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    15.9
  • 作者:
    J. Fangusaro;D. Jones;R. Packer;David H Gutmann;T. Milde;O. Witt;Sabine Mueller;Michael J Fisher;J. Hansford;U. Tabori;Darren R Hargrave;P. Bandopadhayay
  • 通讯作者:
    P. Bandopadhayay

David H Gutmann的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('David H Gutmann', 18)}}的其他基金

Neuronal Regulation of Low-Grade Gliomagenesis
低度胶质瘤发生的神经元调节
  • 批准号:
    10412883
  • 财政年份:
    2022
  • 资助金额:
    $ 76.25万
  • 项目类别:
Neuronal Regulation of Low-Grade Gliomagenesis
低度胶质瘤发生的神经元调节
  • 批准号:
    10596172
  • 财政年份:
    2022
  • 资助金额:
    $ 76.25万
  • 项目类别:
T Cell Regulation of Low-Grade Glioma
低级别胶质瘤的 T 细胞调节
  • 批准号:
    10700099
  • 财政年份:
    2022
  • 资助金额:
    $ 76.25万
  • 项目类别:
Defining the Mechanistic Basis for Neurofibromatosis-1 Nervous System Disease Heterogeneity
定义神经纤维瘤病-1神经系统疾病异质性的机制基础
  • 批准号:
    10533079
  • 财政年份:
    2016
  • 资助金额:
    $ 76.25万
  • 项目类别:
Defining the Mechanistic Basis for Neurofibromatosis-1 Nervous System Disease Heterogeneity
定义神经纤维瘤病-1神经系统疾病异质性的机制基础
  • 批准号:
    10062526
  • 财政年份:
    2016
  • 资助金额:
    $ 76.25万
  • 项目类别:
DEFINING RISK FACTORS FOR NF1-OPTIC GLIOMA
定义 NF1 视神经胶质瘤的危险因素
  • 批准号:
    9171983
  • 财政年份:
    2016
  • 资助金额:
    $ 76.25万
  • 项目类别:
DEFINING RISK FACTORS FOR NF1-OPTIC GLIOMA
定义 NF1 视神经胶质瘤的危险因素
  • 批准号:
    9333268
  • 财政年份:
    2016
  • 资助金额:
    $ 76.25万
  • 项目类别:
Defining the Mechanistic Basis for Neurofibromatosis-1 Nervous System Disease Heterogeneity
定义 Neurophimatosis-1 神经系统疾病异质性的机制基础
  • 批准号:
    10302300
  • 财政年份:
    2016
  • 资助金额:
    $ 76.25万
  • 项目类别:
DEFINING RISK FACTORS FOR NF1-OPTIC GLIOMA
定义 NF1 视神经胶质瘤的危险因素
  • 批准号:
    9751813
  • 财政年份:
    2016
  • 资助金额:
    $ 76.25万
  • 项目类别:
Leveraging Genetically-Engineered Mice to Optimize Pediatric Glioma Management
利用基因工程小鼠优化儿童神经胶质瘤治疗
  • 批准号:
    9297258
  • 财政年份:
    2015
  • 资助金额:
    $ 76.25万
  • 项目类别:

相似海外基金

The potential of using student-conducted ethnographic research as a formative assessment tool in CLIL and EMI courses
在 CLIL 和 EMI 课程中使用学生进行的民族志研究作为形成性评估工具的潜力
  • 批准号:
    24K04145
  • 财政年份:
    2024
  • 资助金额:
    $ 76.25万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Developing a new risk and needs assessment tool for young people who have displayed harmful sexual behaviour
为表现出有害性行为的年轻人开发新的风险和需求评估工具
  • 批准号:
    2886506
  • 财政年份:
    2023
  • 资助金额:
    $ 76.25万
  • 项目类别:
    Studentship
I-Corps: Remote monitoring and assessment tool for spinal care patients
I-Corps:脊柱护理患者的远程监测和评估工具
  • 批准号:
    2321802
  • 财政年份:
    2023
  • 资助金额:
    $ 76.25万
  • 项目类别:
    Standard Grant
SBIR Phase I: PenEEG: An Objective Assessment Tool for Concussion and Recovery Management
SBIR 第一阶段:PenEEG:脑震荡和恢复管理的客观评估工具
  • 批准号:
    2304353
  • 财政年份:
    2023
  • 资助金额:
    $ 76.25万
  • 项目类别:
    Standard Grant
Development of the Dementia-Friendly Environmental Assessment Tool for Japanese care and nursing homes
为日本护理院和疗养院开发痴呆症友好型环境评估工具
  • 批准号:
    22KJ0474
  • 财政年份:
    2023
  • 资助金额:
    $ 76.25万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Implementation of an impact assessment tool to optimize responsible stewardship of genomic data in the cloud
实施影响评估工具以优化云中基因组数据的负责任管理
  • 批准号:
    10721762
  • 财政年份:
    2023
  • 资助金额:
    $ 76.25万
  • 项目类别:
I-Corps: Sensor-based frailty assessment tool using a smart watch
I-Corps:使用智能手表的基于传感器的虚弱评估工具
  • 批准号:
    2311611
  • 财政年份:
    2023
  • 资助金额:
    $ 76.25万
  • 项目类别:
    Standard Grant
DEVELOPMENT OF DIABETES HEALTH LITERACY ASSESSMENT TOOL TO SUPPORT HEALTHCARE PROVIDERS DURING VIRTUAL VISIT
开发糖尿病健康素养评估工具,在虚拟访问期间为医疗保健提供者提供支持
  • 批准号:
    495439
  • 财政年份:
    2023
  • 资助金额:
    $ 76.25万
  • 项目类别:
Development of a diagnostic assessment tool and training app for dyscaliculia to apply in medical treatment and education.
开发计算障碍诊断评估工具和培训应用程序,以应用于医疗和教育。
  • 批准号:
    23K02570
  • 财政年份:
    2023
  • 资助金额:
    $ 76.25万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Injury prevention for rugby-related concussion: development of a comprehensive tackle assessment tool
橄榄球相关脑震荡的伤害预防:开发综合铲球评估工具
  • 批准号:
    23K16737
  • 财政年份:
    2023
  • 资助金额:
    $ 76.25万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了